Back

Hemagglutination inhibition and alternate serologic responses following Influenza A(H3N2) virus infection

Chen, B.; Zambrana, J. V.; Shotwell, A.; Sanchez, N.; Plazaola, M.; Ojeda, S.; Lopez, R.; Stadlbauer, D.; Kuan, G.; Balmaseda, A.; Krammer, F.; Gordon, A.

2026-04-22 infectious diseases
10.64898/2026.04.21.26351404 medRxiv
Show abstract

Background Although the hemagglutination inhibition (HAI) titer remains the gold standard correlate of protection against influenza, it does not fully capture the broader antibody responses that contribute to immunity. MethodsWe analyzed immune responses in paired pre-infection and convalescent sera from 306 RT-PCR-confirmed A/H3N2 infections from two household studies (2014-18) in Managua, Nicaragua. Antibody responses were measured by HAI and enzyme-linked immunosorbent assays (ELISAs) against full-length hemagglutinin (HA), the HA stalk, and neuraminidase (NA). Participants were classified as HAI responders ([&ge;]4-fold HAI rise), alternate responders (no HAI rise but [&ge;]4-fold boost in [&ge;]1 ELISA), or no-response individuals (no [&ge;]4-fold rise in any assay). We compared demographic, clinical, and pre-infection antibody characteristics across these groups. We also analyzed predictors of an NA response. ResultsOverall, 77% of participants had HAI seroconversion or a 4-fold rise. Among the 23% HAI non-responders, 62% had alternate antibody responses. No-response individuals had the highest pre-infection HAI and full-length HA titers (p < 0.0001), the lowest viral loads, and the fewest fever or influenza like illness (ILI) symptoms (p < 0.01). An NA response was more common among symptomatic individuals (p = 0.0483) and those with low or high baseline NA titers. ConclusionsHigh baseline HAI titers can limit detectable 4-fold rises and are associated with milder illness. Evaluating additional immune responses may capture a more complete picture of the host response to infection, thereby improving surveillance and informing vaccine development.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Influenza and Other Respiratory Viruses
44 papers in training set
Top 0.1%
22.1%
2
Clinical Infectious Diseases
231 papers in training set
Top 0.2%
14.1%
3
The Journal of Infectious Diseases
182 papers in training set
Top 0.2%
9.0%
4
BMC Infectious Diseases
118 papers in training set
Top 0.4%
6.2%
50% of probability mass above
5
Open Forum Infectious Diseases
134 papers in training set
Top 0.4%
3.6%
6
Vaccine
189 papers in training set
Top 0.8%
3.5%
7
PLOS ONE
4510 papers in training set
Top 40%
3.5%
8
The Lancet Infectious Diseases
71 papers in training set
Top 1%
2.4%
9
Nature Communications
4913 papers in training set
Top 51%
1.7%
10
The Lancet
16 papers in training set
Top 0.2%
1.7%
11
The Lancet Microbe
43 papers in training set
Top 0.7%
1.6%
12
eBioMedicine
130 papers in training set
Top 2%
1.6%
13
BMC Medicine
163 papers in training set
Top 5%
1.3%
14
Wellcome Open Research
57 papers in training set
Top 1%
1.3%
15
BMJ Open
554 papers in training set
Top 11%
1.2%
16
Journal of Infection
71 papers in training set
Top 2%
1.2%
17
Annals of Internal Medicine
27 papers in training set
Top 0.6%
1.2%
18
New England Journal of Medicine
50 papers in training set
Top 0.6%
1.2%
19
Immunology
29 papers in training set
Top 0.7%
1.1%
20
Journal of Clinical Microbiology
120 papers in training set
Top 1%
0.9%
21
Scientific Reports
3102 papers in training set
Top 73%
0.8%
22
Frontiers in Immunology
586 papers in training set
Top 7%
0.8%
23
EClinicalMedicine
21 papers in training set
Top 1%
0.7%
24
International Journal of Epidemiology
74 papers in training set
Top 3%
0.7%
25
eClinicalMedicine
55 papers in training set
Top 2%
0.7%
26
PLOS Pathogens
721 papers in training set
Top 10%
0.6%
27
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 5%
0.6%
28
Vaccine: X
19 papers in training set
Top 0.4%
0.6%
29
PLOS Computational Biology
1633 papers in training set
Top 28%
0.6%